Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRVS with free AI briefings, catalyst countdowns, and dilution alerts.

CRVS · Corvus Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$202.9M Cash on Hand
44.1mo Cash Runway
Follow CRVS by email Get an email when CRVS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRVS, unsubscribe in one click. Privacy

📣 What CRVS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Mupadolimab (CPI-006) Covid-19 Phase 3 · NCT04734873 Terminated
Soquelitinib (CPI-818) Peripheral T-Cell Lymphoma, Not Otherwise Specified Phase 3 · NCT06561048 Recruiting
Ciforadenant (CPI-444) Multiple Myeloma Phase 1 · NCT04280328 Completed

Also used in these trials (approved or third-party drugs, not CRVS's own candidates): Belinostat, Pralatrexate, Daratumumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRVS holds $202.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.8M/quarter from operations, an estimated runway of 44.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 27 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRVS files for a raise →

👥 Who Owns CRVS

Insiders 27.7% Other 5%+ holders 7.2% Institutions (247 holders) 65.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Peter A. Thompson
Director, 10% owner · +2.89M options
Insider 8,819,091 10.45% 2026-01-28
ORBIMED ADVISORS LLC
Director, 10% owner · +2.84M options
Insider 8,609,091 10.21% 2026-01-23
Sirenia Capital Management LP Institution (13G, 5%+) 6,831,828 8.10% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 6,325,157 7.50% 2026-06-30
Richard A. Miller 5%+ holder (13G) 6,085,922 7.21% 2025-12-31
Terry P Gould
Director, 10% owner · +15,000 options
Insider 3,275,616 3.88% 2024-06-13
Richard A Md Miller
President and CEO, Director · +1.75M options
Insider 2,331,742 2.76% 2026-05-18
William Benton Jones
SVP, Pharmaceutical Development · +700,000 options
Insider 173,130 0.21% 2025-06-04
den Broek Richard van
Director · +45,000 options
Insider 160,000 0.19% 2025-04-08
David Scott Moore
Director · +45,000 options
Insider 21,700 0.03% 2026-06-11
Jeffrey Arcara
Chief Business Officer · +550,000 options
Insider 4,500 0.01% 2026-11-11

Share count 84,353,126 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRVS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRVS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.